Lineage Cell Therapeutics (XTAE:LCTX) Margin of Safety % (DCF FCF Based) : N/A (As of Dec. 11, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Lineage Cell Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Lineage Cell Therapeutics's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Lineage Cell Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Margin of Safety % (DCF FCF Based) falls into.

Lineage Cell Therapeutics Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.